Lipoprotein(a) is largely genetically determined and causally increases atherosclerotic cardiovascular disease risk.

Evidence from genetic studies, large-scale meta-analyses, and clinical trials confirms that Lipoprotein(a) [Lp(a)] is a distinct, genetically determined lipid particle and a potent causal driver of cardiovascular disease. Unlike standard cholesterol markers, Lp(a) remains largely unaffected by lifestyle modifications, making it a critical focus for identifying residual risk in patients with established disease or strong family histories.

Clinical and effectiveness evidence

Extensive epidemiological data and Mendelian randomization studies establish elevated Lp(a) as an independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction and stroke.

• Independent Risk: Analysis of data from trials like FOURIER and AIM-HIGH demonstrates that high Lp(a) levels predict major adverse cardiovascular events (MACE) even when LDL cholesterol is lowered to target levels (e.g., <55 mg/dL) using statins or PCSK9 inhibitors.
• Causality: Mendelian randomization studies, which use genetic variants as proxies for lifelong exposure, show a linear relationship between genetically predicted Lp(a) and coronary heart disease risk. This evidence eliminates many of the confounding factors found in traditional observational studies.
• Risk Thresholds: Risks generally rise significantly when Lp(a) levels exceed 50 mg/dL (approximately 125 nmol/L), though some evidence suggests risk increases continuously across the distribution.

Genetic determination

The concentration of Lp(a) in the blood is nearly entirely fixed by birth, dictated by the LPA gene on chromosome 6.

• Heritability: Between 70% and over 90% of the variance in Lp(a) levels is explained by inheritance. The primary determinant is the number of Kringle IV type 2 (KIV-2) repeats; fewer repeats result in smaller protein isoforms that are secreted more efficiently into the plasma, leading to higher levels.
• Stability: Because levels are genetically programmed, they fluctuate minimally throughout a person's life. Non-genetic factors such as diet, exercise, and most standard medications contribute only about 3% to the total variance.

Mechanistic explanations

Lp(a) promotes cardiovascular disease through a "triple threat" of biological pathways:

• Pro-atherogenic: Like LDL, the Lp(a) particle contains apolipoprotein B-100, allowing it to infiltrate the arterial wall and promote foam cell formation and plaque buildup.
• Pro-inflammatory: Lp(a) is the primary carrier of oxidized phospholipids (OxPL) in the blood. These phospholipids trigger the NLRP3 inflammasome, leading to arterial wall inflammation and the calcification of heart valves.
• Pro-thrombotic: The apolipoprotein(a) component of the particle shares significant structural homology with plasminogen. This allows it to compete for binding sites, potentially inhibiting fibrinolysis (the breakdown of blood clots) and increasing the risk of acute events.

Bottom line

Lipoprotein(a) is a highly heritable, independent, and causal risk factor for cardiovascular disease that is not adequately captured by standard lipid panels. For an individual, especially one in their 70s, a one-time measurement can provide critical insight into residual cardiovascular risk that remains even after controlling traditional factors like LDL cholesterol and blood pressure.